Extension in AS: Sustainability of Benefits, Safety and Tolerability
| Status: | Completed |
|---|---|
| Conditions: | Neurology, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/8/2018 |
| Start Date: | November 6, 2013 |
| End Date: | March 16, 2018 |
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
This 3-year extension study aims at making available the treatment with secukinumab in
prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III
study CAIN457F2305, defined as "core study", as well as to generate additional data on the
sustainability of clinical benefits, safety and tolerability during long-term administration
of secukinumab.
prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III
study CAIN457F2305, defined as "core study", as well as to generate additional data on the
sustainability of clinical benefits, safety and tolerability during long-term administration
of secukinumab.
Inclusion Criteria: patients having completed the "core study" CAIN457F2305, indication for
treatment extension. -- Exclusion Criteria: history of hypersensitivity to secukinumab or
to any drug of similar chemical classes, use of any investigational drug other than
secukinumab during the "core study" CAIN457F2305.
We found this trial at
6
sites
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials